The limbic and neocortical contribution of α‐synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Alzheimer's & Dementia

• Publication date

  2018-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jalz.2017.09.014PMID 29100980PMCID PMC5899889
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

  2017cited by this paper
• Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology

  2016cited by this paper
• Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes

  2015cited by this paper
• Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum

  2015cited by this paper
• Clinicians' ability to diagnose dementia with Lewy bodies is not affected by β-amyloid load

  2015cited by this paper
• α-Synuclein strains cause distinct synucleinopathies after local and systemic administration

  2015cited by this paper
• Inhibition of amyloid-β plaque formation by α-synuclein

  2015cited by this paper
• Using commonality analysis in multiple regressions: a tool to decompose regression effects in the face of multicollinearity

  2014cited by this paper
• Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys

  2014cited by this paper
• Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.

  2013cited by this paper
• Prion-like spreading of pathological α-synuclein in brain

  2013cited by this paper
• Distinct a-Synuclein Strains Differentially Promote Tau Inclusions in Neurons

  2013cited by this paper
• Neuropathology of dementia in a large cohort of patients with Parkinson's disease.

  2013cited by this paper
• Multimodality imaging characteristics of dementia with Lewy bodies.

  2012cited by this paper
• Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

  2012cited by this paper
• Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice

  2012cited by this paper
• Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes.

  2012cited by this paper
• Neuropathologically defined subtypes of Alzheimer’s disease differ significantly from neurofibrillary tangle-predominant dementia

  2012cited by this paper
• Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

  2012cited by this paper
• Neuropathologic substrates of Parkinson disease dementia

  2012cited by this paper
• Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort.

  2011cited by this paper
• Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy

  2011cited by this paper
• Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

  2011cited by this paper
• National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach

  2011cited by this paper
• Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies

  2011cited by this paper
• Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

  2011cited by this paper
• Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

  2010cited by this paper
• Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.

  2010cited by this paper
• Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology

  2009cited by this paper
• Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

  2008cited by this paper
• Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

  2008cited by this paper
• Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed Cases

  2008cited by this paper
• Evaluation of alpha-synuclein immunohistochemical methods used by invited experts.

  2008cited by this paper
• Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients

  2008cited by this paper
• The progression of pathology in longitudinally followed patients with Parkinson’s disease

  2008cited by this paper
• Irreversible motor impairment in young addicts – ephedrone, manganism or both?

  2007cited by this paper
• Predictors of Survival in Dementia with Lewy Bodies and Parkinson Dementia

  2007cited by this paper
• Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease

  2006cited by this paper
• Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases

  2005cited by this paper
• Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s disease

  2004cited by this paper
• DLB fluctuations

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein

  2003cited by this paper
• Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.

  2003cited by this paper
• Phases of Aβ-deposition in the human brain and its relevance for the development of AD

  2002cited by this paper
• beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

  2001cited by this paper
• β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

  2001cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease

  2000cited by this paper
• [The Unified Parkinson's Disease Rating Scale].

  2000cited by this paper
• Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease.

  1999cited by this paper
• Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups.

  1999influential reference
• Plaque‐Only Alzheimer Disease is Usually the Lewy Body Variant, and Vice Versa

  1993cited by this paper
• Global Deterioration Scale (GDS).

  1988cited by this paper
• Unified Parkinson's Disease Rating Scale

  1987cited by this paper
• This Work Is Licensed under a Creative Commons Attribution 4.0 International License Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias

  year unknowncited by this paper

• Tau, amyloid-β and α-synuclein co-pathologies synergistically enhance neuroinflammation and hippocampal neuron loss.

  2026cites this paper
• Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies—Current View

  2025cites this paper
• Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein

  2025cites this paper
• Impact of hippocampal α‐synuclein oligomers on cognitive trajectory in patients with dementia with Lewy bodies

  2025cites this paper
• Cerebrospinal fluid sTREM2 mediates the associations of α-synuclein with tau pathology in older adults without dementia: two population-based study

  2025cites this paper
• Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants

  2025cites this paper
• Hippocampal subfields: volume, neuropathological vulnerability and cognitive decline in Alzheimer’s and Parkinson’s disease

  2025cites this paper
• Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer’s disease copathologies

  2025cites this paper
• Cerebral microbleeds: prevalence and relationship to clinical features in cognitive impairment with lewy body disease

  2025cites this paper
• Rest–Activity Disturbances Correlate with Core Features in Dementia with Lewy Bodies

  2025cites this paper
• Core Clinical Features Associated With Survival in Patients With Dementia With Lewy Bodies.

  2025cites this paper
• Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer’s Disease

  2025cites this paper
• Tau, amyloid-β and α-synuclein co-pathologies synergistically enhance neuroinflammation and neuropathology

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies

  2025cites this paper
• Lewy body co‐pathology in Alzheimer's disease and primary age‐related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns

  2024cites this paper
• Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change

  2024cites this paper
• Plasma lipidomic signatures of dementia with Lewy bodies revealed by machine learning, and compared to Alzheimer's disease

  2024cites this paper
• Clinical, neuropathological, and molecular characteristics of rapidly progressive dementia with Lewy bodies: a distinct clinicopathological entity?

  2024cites this paper
• Association of quantitative histopathology measurements with antemortem medial temporal lobe cortical thickness in the Alzheimer’s disease continuum

  2024cites this paper
• Cognitive dysfunction in animal models of human lewy-body dementia

  2024cites this paper
• Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.

  2024cites this paper
• Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults

  2024cites this paper
• Neuroinflammation is associated with Alzheimer’s disease co-pathology in dementia with Lewy bodies

  2024cites this paper
• Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies

  2024cites this paper
• Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.

  2024cites this paper
• Longitudinal Free‐Water Changes in Dementia with Lewy Bodies

  2024cites this paper
• Under-Diagnosis of Dementia with Lewy Bodies in Individuals Racialized as Black: Hypotheses Regarding Potential Contributors

  2024cites this paper
• Clinical effects of Lewy body pathology in cognitively impaired individuals

  2023cites this paper
• Mild cognitive impairment in dementia with Lewy bodies: an update and outlook

  2023cites this paper
• Mixed Dementia Alzheimer and Lewy body with congenital diseases: Case Study

  2023cites this paper
• Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia

  2023cites this paper
• Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease.

  2023cites this paper
• β-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies

  2023cites this paper
• A how-to guide for a precision medicine approach to the diagnosis and treatment of Alzheimer's disease

  2023cites this paper
• A Precision Medicine Approach to Dementia Care: Syndrome, Etiology, and Copathology.

  2023cites this paper
• Hippocampal Reduction of α-Synuclein via RNA Interference Improves Neuropathology in Alzheimer’s Disease Mice

  2023cites this paper
• Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions.

  2023cites this paper
• Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy

  2023cites this paper
• Clinical update on dementia with Lewy bodies for primary care NPs

  2023cites this paper
• Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration

  2022cites this paper
• RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD

  2022cites this paper
• Characteristics of Cortical Atrophy and White Matter Lesions Between Dementia With Lewy Bodies and Alzheimer's Disease: A Case-Control Study

  2022cites this paper
• Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data

  2022cites this paper
• Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia

  2022cites this paper
• Neuropathological substrates of cognition in Parkinson's disease.

  2022cites this paper
• Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias.

  2022cites this paper
• Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies.

  2022cites this paper
• Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies

  2022cites this paper
• Clinical Trajectories at the End of Life in Autopsy-Confirmed Dementia Patients With Alzheimer Disease and Lewy Bodies Pathologies

  2022cites this paper
• Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?

  2022cites this paper
• Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases

  2022cites this paper
• Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures

  2022cites this paper
• Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design

  2022cites this paper
• Inflammation in dementia with Lewy bodies.

  2022cites this paper
• Advances in dementia with Lewy bodies

  2021cites this paper
• Regional Brain Stiffness Analysis of Dementia with Lewy Bodies

  2021cites this paper
• Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders.

  2021cites this paper
• Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies.

  2021cites this paper
• Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases

  2021cites this paper
• Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges

  2021influential citation
• Vascular Lesions, APOE ε4, and Tau Pathology in Alzheimer Disease.

  2021cites this paper
• A Neurologist's Practical Approach to Cognitive Impairment.

  2021cites this paper
• Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias

  2021cites this paper
• Significant Overlap of α-Synuclein, Amyloid-β, and Phospho-Tau Pathologies in Neuropathological Diagnosis of Lewy-related Pathology: Evidence from China Human Brain Bank

  2021cites this paper
• β-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia

  2021cites this paper
• F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies

  2020influential citation
• Neuroinflammation and protein pathology in Parkinson’s disease dementia

  2020cites this paper
• [Fluctuation of cognitive functions in dementia with Lewy bodies].

  2020cites this paper
• Dementia, A General Medical Practitioner’s Concern: A Review

  2020cites this paper
• Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy

  2020cites this paper
• β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

  2020cites this paper
• Neuroinflammation in dementia with Lewy bodies: a human post-mortem study

  2020cites this paper
• Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution

  2020cites this paper
• Alzheimer’s Disease Neuropathological Comorbidities are Common in the Younger-Old

  2020cites this paper
• Striatal dopamine transporter activity may predict β-amyloid pathology in dementia with Lewy bodies

  2020influential citation
• Microbleeds in dementia with Lewy bodies

  2020cites this paper
• Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases

  2020influential citation
• β-Amyloid PET and neuropathology in dementia with Lewy bodies

  2019cites this paper
• Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions

  2019cites this paper
• Lewy Body Dementias

  2019cites this paper
• Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia

  2019cites this paper
• Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia

  2019cites this paper
• Fluctuating cognition in the Lewy body dementias.

  2019cites this paper
• Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration

  2019cites this paper
• Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders

  2019cites this paper
• Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease

  2019cites this paper
• Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions

  2019cites this paper
• Neuropathological and genetic characteristics of a post-mortem series of cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob's disease.

  2019cites this paper
• Dementia with Lewy bodies: Challenges in the diagnosis and management

  2019cites this paper
• Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?

  2018cites this paper
• The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders

  2018cites this paper